Table 3 Multivariate analysis of prognostic factors for disease-free survival in endometrial cancer
From: Preoperative serum CA125: a useful marker for surgical management of endometrial cancer
| Factor | No of patients | P value | HR | 95.0% CI for HR | |
|---|---|---|---|---|---|
| lower | upper | ||||
| FIGO stage | |||||
| I | 769 | 0.01 | 1 | ||
| II | 85 | 0.15 | 1.40 | 0.88 | 2.20 |
| III | 116 | 0.85 | 1.04 | 0.69 | 1.56 |
| IV | 25 | 0.00 | 2.34 | 1.38 | 3.97 |
| Histology grade | |||||
| 1 | 495 | 0.00 | 1 | ||
| 2 | 367 | 0.16 | 1.28 | 0.91 | 1.81 |
| 3 | 133 | 0.00 | 2.46 | 1.78 | 3.42 |
| Positive peritoneal cytology | |||||
| No | 964 | 1 | |||
| yes | 31 | 0.00 | 3.24 | 1.89 | 5.32 |
| Preoperative serum CA125 | |||||
| ≤25U/mL | 645 | 0.00 | 1 | ||
| 25-30 U/mL | 65 | 0.00 | 2.86 | 1.71 | 4.78 |
| 30-45 U/mL | 109 | 0.06 | 1.54 | 0.98 | 2.41 |
| >45 U/mL | 176 | 0.00 | 2.41 | 1.69 | 3.46 |